VANCOUVER, Sept. 9, 2015 /CNW/ - The Board of Directors of LifeSciences BC announced today at their Annual General Meeting, that James P. Hatton Q.C. has been appointed new Chairman of the LifeSciences BC Board of Directors. He is taking over from outgoing Chair, Gordon McCauley, who has served on the Board of Directors since 2008 and will continue in the Past-Chair role. The appointment is effective immediately.
Hatton, a partner with the firm Farris, Vaughan, Wills & Murphy LLP, is a commercial solicitor with more than 25 years' experience in assisting companies to utilise the value of their intellectual property assets. His experience in the practice areas of Biotechnology Law and Intellectual Property Law, lead to his impressive recognition as Vancouver's 2013 "Biotechnology Law Lawyer of the Year". He is also listed as a leading practitioner in the Canadian Legal Lexpert Directory, repeatedly recommended in the fields of biotechnology and technology transactions.
"We are extremely fortunate to have such an esteemed lawyer who has built a life-long practice in biotechnology and intellectual property law to guide our course over the next few years," said Paul Drohan, President & CEO of LifeSciences BC. "I look forward to working alongside James, benefitting from his judgement and counsel, as we move our life science cluster to not only one of the best in Canada – but in the world."
It was also announced that Nancy Harrison, Board of Director member since 2012, will take over as Vice Chair.
Nancy Harrison is Co-founder and Chief Business Officer of MSI Methylation Sciences, a private venture backed development company with a novel treatment of depression in a Phase II clinical trial. She is a former Partner and Senior Vice President of Ventures West Management Inc. Nancy spent 13 years with Ventures West leading its life sciences practice in Canada and the U.S. She is one of the most experienced life sciences investors in the Canadian venture capital industry and was instrumental in Ventures West's involvement in the sector and with companies such as Angiotech Pharmaceuticals Inc., AnorMed Inc., Salmedix Inc. and Oncogenix Pharmaceuticals Inc. During her time with Ventures West, the firm grew from approximately $80 million to over $750 million. Nancy has an undergraduate degree in Engineering from Queen's University and an MBA from McGill University.
About LifeSciences BC
LifeSciences BC is a not-for-profit, non-government, industry association that supports and represents the life sciences community of British Columbia through leadership, facilitation of investment and partnering, advocacy, and promotion of our world-class science and industry.
Life sciences sectors, from biopharmaceuticals and medical technology, to digital health and medical devices, are integrated into our organization and all that we do, ensuring that no life sciences sector is working in isolation — and that all sectors come together in a comprehensive, complementary and coordinated fashion.
Throughout the year, LifeSciences BC undertakes numerous programs and projects in support of these sectors. These include public policy initiatives, facilitating linkages between global industry and our local organizations, raising the profile of our industry internationally and thus facilitating investment and global partnering opportunities, and helping nurture economic development in British Columbia through the life sciences industry.
SOURCE LifeSciences British Columbia
Image with caption: "James P. Hatton Q.C. Chairman, Board of Directors, LifeSciences BC. (CNW Group/LifeSciences British Columbia)". Image available at: http://photos.newswire.ca/images/download/20150909_C5825_PHOTO_EN_493572.jpg
For further information: Susan Ogilvie, Manager, Communications & External Affairs, Phone: 604-669-9909 - EXT 106, Cell: 604-218-5188, Email: [email protected]